FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma

By afschroeder • July 20, 2025

Smyth EC, Kim KM, Rha SY, Wainberg ZA, Honeycutt H, Sommermann E, Ochiai A. FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma. Cancer Treat Rev. 2025 May 26;139:102971. doi: 10.1016/j.ctrv.2025.102971. Epub ahead of print. PMID: 40680491.

Tags: biomarkers, Fgfr2b, Fibroblast growth factor receptor, Fibroblast growth receptor 2b, gastric cancer, Hematology/Oncology, Publications, targeted therapy

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq[...]

Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients

Moore TW, Spiliotopoulos E, Callahan RL, Kirschbaum CW, Bailey CF, Kim HJ, Roskams-Hieter B, Goncalves F, Keith D, Grossberg AJ, Spellman PT, Mills GB, Sears[...]

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]